N-叔丁基-#-苯基硝酮
N-叔丁基-#-苯基硝酮 性质
| 熔点 | 73-74 °C(lit.) |
|---|---|
| 沸点 | 283℃ |
| 密度 | 0.990 |
| 折射率 | 1.5480 (estimate) |
| 闪点 | 119℃ |
| 储存条件 | Store at <= 20°C. |
| 溶解度 | 可溶于DMSO |
| 形态 | 粉末 |
| 酸度系数(pKa) | 1.50±0.53(Predicted) |
| 颜色 | 白色 |
| 水溶解性 | Soluble in DMSO (10 mg/ml), chloroform (50 mg/ml), and water (20 mg/ml). |
| Merck | 14,7056 |
| BRN | 2044028 |
| CAS 数据库 | 3376-24-7(CAS DataBase Reference) |
| EPA化学物质信息 | 2-Propanamine, 2-methyl-N-(phenylmethylene)-, N-oxide (3376-24-7) |
N-叔丁基-#-苯基硝酮 用途与合成方法
|
COX-2
|
Reactive oxygen species (ROS)
|
N-tert-Butyl-α-phenylnitrone (PBN) (25-100 µM) treatment leads to a significant decrease in 2,2'-azobis (2-amidinopropane) dihydrochloride (AAPH)-induced intracellular ROS accumulation. N-tert-Butyl-α-phenylnitrone also attenuates AAPH-induced cytotoxicity, matrix degradation, and apoptosis. N-tert-Butyl-α-phenylnitrone suppresses AAPH-induced activation of ERK/MAPK pathway. N-tert-Butyl-α-phenylnitrone has the potenial for intervertebral disc degeneration (IDD) research.
N-tert-Butyl-α-phenylnitrone (PBN; 100 mg/kg; intraperitoneal injection; twice a day; C57Bl/6 mice) treatment not only abolishes the LPS-induced lipid peroxidation, nitrotyrosine residue levels, and GSH depletion, but also decreases the incidence of external malformations.
| Animal Model: | C57Bl/6 mice induced by lipopolysaccharide (LPS) |
| Dosage: | 100 mg/kg |
| Administration: | Intraperitoneal injection; twice a day (on gestational day 8) |
| Result: | Abolished LPS-induced lipid peroxidation, nitrotyrosine residues, and GSH depletion. |
N-叔丁基-#-苯基硝酮 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-01-25 | HY-128463 | N-叔丁基-#-苯基硝酮 | 3376-24-7 | 100mg | 900 |
| 2024-01-25 | HY-128463 | N-叔丁基-#-苯基硝酮 | 3376-24-7 | 10mM * 1mLin DMSO | 990 |
